- Conditions
- Healthy Adults
- Interventions
- Crucera-SGS, Meriva 500-SF
- Dietary Supplement
- Lead sponsor
- Johns Hopkins University
- Other
- Eligibility
- 18 Years to 70 Years
- Enrollment
- 25 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2017 – 2019
- U.S. locations
- 1
- States / cities
- Baltimore, Maryland
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 1–24
of 993
matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
- Conditions
- Chronic Obstructive Pulmonary Disease (COPD), Smoking, Smoking Cessation, Idiopathic Pulmonary Fibrosis (IPF), Rheumatoid Arthritis-Associated Interstitial Lung Disease, Scleroderma-Associated Interstitial Lung Disease (SSC-ILD)
- Interventions
- Not listed
- Lead sponsor
- Weill Medical College of Cornell University
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 2,000 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2012 – 2028
- U.S. locations
- 1
- States / cities
- New York, New York
- Conditions
- Overweight, Obesity
- Interventions
- NNC0174-0833
- Drug
- Lead sponsor
- Novo Nordisk A/S
- Industry
- Eligibility
- 18 Years to 80 Years
- Enrollment
- 33 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2020 – 2021
- U.S. locations
- 2
- States / cities
- Miami, Florida • Orlando, Florida
- Conditions
- Anemia, Necrotizing Enterocolitis
- Interventions
- Near Infrared Spectroscopy, Non-invasive Image-based Anemia Assessment
- Device · Other
- Lead sponsor
- Emory University
- Other
- Eligibility
- 1 Day to 5 Days
- Enrollment
- 324 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2016 – 2026
- U.S. locations
- 3
- States / cities
- Atlanta, Georgia
- Conditions
- RAI1 Gene 17P11.2 Deletion+Duplication
- Interventions
- Electroencephalography/Polysomnography (EEG/PSG), Skin Biopsy, Blood draw
- Diagnostic Test · Procedure
- Lead sponsor
- Baylor College of Medicine
- Other
- Eligibility
- 1 Month to 80 Years
- Enrollment
- 90 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2024 – 2027
- U.S. locations
- 1
- States / cities
- Houston, Texas
- Conditions
- Hemophilia, Thrombosis, Hemophilia A, Hemophilia B, Sickle Cell Disease, Glanzmann Thrombasthenia, Bleeding Disorder, Blood Disorder, Von Willebrand Diseases
- Interventions
- Not listed
- Lead sponsor
- American Thrombosis and Hemostasis Network
- Network
- Eligibility
- Not listed
- Enrollment
- 200,000 participants
- Timeline
- 2024 – 2055
- U.S. locations
- 1
- States / cities
- Hickory, North Carolina
- Conditions
- Childhood Atypical Teratoid/Rhabdoid Tumor, Childhood Central Nervous System Germ Cell Tumor, Childhood Cerebral Anaplastic Astrocytoma, Childhood Cerebral Astrocytoma, Childhood Choroid Plexus Neoplasm, Childhood Craniopharyngioma, Childhood Grade I Meningioma, Childhood Grade II Meningioma, Childhood Grade III Meningioma, Childhood Infratentorial Ependymoma, Childhood Oligodendroglioma, Childhood Supratentorial Ependymoma, Ependymoma, Newly Diagnosed Childhood Ependymoma, Recurrent Childhood Cerebellar Astrocytoma, Recurrent Childhood Cerebral Astrocytoma, Recurrent Childhood Ependymoma, Recurrent Childhood Medulloblastoma, Recurrent Childhood Supratentorial Embryonal Tumor, Not Otherwise Specified, Recurrent Childhood Visual Pathway Glioma
- Interventions
- Cytology Specimen Collection Procedure
- Other
- Lead sponsor
- Children's Oncology Group
- Network
- Eligibility
- Up to 18 Years
- Enrollment
- 1,258 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2004 – 2018
- U.S. locations
- 163
- States / cities
- Birmingham, Alabama • Phoenix, Arizona • Little Rock, Arkansas + 123 more
- Conditions
- Colorectal Cancer
- Interventions
- Immunochemical Fecal Occult Blood Test (I-FOBT) Kit, Standard Intervention (SI) Educational Materials, CARES Intervention Educational Materials, Baseline Visit Survey, Follow-up Questionnaire
- Other
- Lead sponsor
- H. Lee Moffitt Cancer Center and Research Institute
- Other
- Eligibility
- 50 Years to 75 Years
- Enrollment
- 514 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2011 – 2022
- U.S. locations
- 1
- States / cities
- Tampa, Florida
- Conditions
- Glioblastoma Multiforme, Anaplastic Astrocytoma
- Interventions
- Super-Selective Intraarterial Intracranial Infusion of BEVACIZUMAB
- Drug
- Lead sponsor
- Northwell Health
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 30 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2009 – 2014
- U.S. locations
- 1
- States / cities
- New York, New York
- Conditions
- Multiple Myeloma and Plasma Cell Neoplasm
- Interventions
- carmustine, cyclophosphamide, dexamethasone, etoposide, filgrastim, mitoxantrone hydrochloride, recombinant interferon alfa, sargramostim, bone marrow ablation with stem cell support, peripheral blood stem cell transplantation, radiation therapy
- Drug · Procedure
- Lead sponsor
- Masonic Cancer Center, University of Minnesota
- Other
- Eligibility
- Up to 70 Years
- Enrollment
- 87 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2000 – 2003
- U.S. locations
- 1
- States / cities
- Minneapolis, Minnesota
- Conditions
- Sepsis, Burn Injury, Wound Healing, Critical Illness, Multiple Organ Dysfunction Syndrome
- Interventions
- Observational Cohort (No Intervention)
- Other
- Lead sponsor
- Henry M. Jackson Foundation for the Advancement of Military Medicine
- Other
- Eligibility
- 18 Years to 80 Years
- Enrollment
- 80 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2027
- U.S. locations
- 3
- States / cities
- Tampa, Florida • Atlanta, Georgia • Houston, Texas
- Conditions
- End Stage Renal Disease
- Interventions
- Expanded Tregs
- Drug
- Lead sponsor
- Northwestern University
- Other
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 10 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2014 – 2016
- U.S. locations
- 1
- States / cities
- Chicago, Illinois
- Conditions
- Diabetes Mellitus, Type 1
- Interventions
- Closed-loop session
- Device
- Lead sponsor
- Sansum Diabetes Research Institute
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 19 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2008 – 2010
- U.S. locations
- 1
- States / cities
- Santa Barbara, California
- Conditions
- Non-small Cell Lung Cancer, Lung Cancer, Metastatic Lung Cancer, NSCLC
- Interventions
- nivolumab and ablation
- Drug
- Lead sponsor
- howard safran
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 10 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2016 – 2018
- U.S. locations
- 2
- States / cities
- Providence, Rhode Island
- Conditions
- Hematopoietic and Lymphoid Cell Neoplasm, Malignant Solid Neoplasm
- Interventions
- 6 Minute Walk Functional Test, Behavioral Intervention, Survey Administration, Timed Get Up and Go Test
- Other · Behavioral
- Lead sponsor
- M.D. Anderson Cancer Center
- Other
- Eligibility
- 6 Years to 29 Years
- Enrollment
- 60 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2028
- U.S. locations
- 2
- States / cities
- Dallas, Texas • Houston, Texas
- Conditions
- Hemorrhagic Shock, Trauma Injury
- Interventions
- Low Titer Group O Whole Blood (LTOWB), Placebo, Tranexamic Acid (TXA), Component Therapy (CT)
- Biological · Drug
- Lead sponsor
- Philip Spinella
- Other
- Eligibility
- Up to 17 Years
- Enrollment
- 1,000 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2028
- U.S. locations
- 23
- States / cities
- Tucson, Arizona • Little Rock, Arkansas • Sacramento, California + 18 more
- Conditions
- Renal Cell Carcinoma
- Interventions
- Lenvatinib, Pembrolizumab, Research blood collection
- Drug · Procedure
- Lead sponsor
- Washington University School of Medicine
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 11 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2024
- U.S. locations
- 2
- States / cities
- Palo Alto, California • St Louis, Missouri
- Conditions
- Gout, Hyperuricemia
- Interventions
- Subsidy for food purchases and dietitian education
- Other
- Lead sponsor
- Johns Hopkins University
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 43 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2018 – 2019
- U.S. locations
- 2
- States / cities
- Woodlawn, Maryland • Boston, Massachusetts
- Conditions
- Carcinoid Tumor, Carcinoid Tumor of GI System, Neuroendocrine Tumors
- Interventions
- Nivolumab, Cabozantinib
- Drug
- Lead sponsor
- Dana-Farber Cancer Institute
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 19 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2024
- U.S. locations
- 2
- States / cities
- Boston, Massachusetts
- Conditions
- Spinal Muscular Atrophy
- Interventions
- Not listed
- Lead sponsor
- Massachusetts General Hospital
- Other
- Eligibility
- Not listed
- Enrollment
- 1,000 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- Started 2016
- U.S. locations
- 1
- States / cities
- Boston, Massachusetts
- Conditions
- Borderline Ovarian Clear Cell Tumor, Borderline Ovarian Serous Tumor, Cervical Adenocarcinoma, Cervical Adenosquamous Carcinoma, Cervical Small Cell Carcinoma, Cervical Squamous Cell Carcinoma, Not Otherwise Specified, Childhood Embryonal Rhabdomyosarcoma, Childhood Malignant Ovarian Germ Cell Tumor, Endometrioid Stromal Sarcoma, Gestational Trophoblastic Tumor, Malignant Mesothelioma, Malignant Ovarian Epithelial Tumor, Melanoma, Neoplasm of Uncertain Malignant Potential, Ovarian Brenner Tumor, Ovarian Clear Cell Cystadenocarcinoma, Ovarian Serous Cystadenocarcinoma, Paget Disease of the Vulva, Recurrent Cervical Carcinoma, Recurrent Fallopian Tube Carcinoma, Recurrent Ovarian Carcinoma, Recurrent Ovarian Germ Cell Tumor, Recurrent Primary Peritoneal Carcinoma, Recurrent Uterine Corpus Carcinoma, Recurrent Vaginal Carcinoma, Recurrent Vulvar Carcinoma, Stage I Ovarian Cancer, Stage I Uterine Corpus Cancer, Stage I Vaginal Cancer, Stage I Vulvar Cancer, Stage IA Cervical Cancer, Stage IA Fallopian Tube Cancer, Stage IA Ovarian Cancer, Stage IA Ovarian Germ Cell Tumor, Stage IB Cervical Cancer, Stage IB Fallopian Tube Cancer, Stage IB Ovarian Cancer, Stage IB Ovarian Germ Cell Tumor, Stage IC Fallopian Tube Cancer, Stage IC Ovarian Cancer, Stage IC Ovarian Germ Cell Tumor, Stage II Ovarian Cancer, Stage II Uterine Corpus Cancer, Stage II Vaginal Cancer, Stage II Vulvar Cancer, Stage IIA Cervical Cancer, Stage IIA Fallopian Tube Cancer, Stage IIA Ovarian Cancer, Stage IIA Ovarian Germ Cell Tumor, Stage IIB Cervical Cancer, Stage IIB Fallopian Tube Cancer, Stage IIB Ovarian Cancer, Stage IIB Ovarian Germ Cell Tumor, Stage IIC Fallopian Tube Cancer, Stage IIC Ovarian Cancer, Stage IIC Ovarian Germ Cell Tumor, Stage III Borderline Ovarian Surface Epithelial-Stromal Tumor, Stage III Cervical Cancer, Stage III Uterine Corpus Cancer, Stage III Vaginal Cancer, Stage III Vulvar Cancer, Stage IIIA Fallopian Tube Cancer, Stage IIIA Ovarian Cancer, Stage IIIA Ovarian Germ Cell Tumor, Stage IIIA Primary Peritoneal Cancer, Stage IIIB Fallopian Tube Cancer, Stage IIIB Ovarian Cancer, Stage IIIB Ovarian Germ Cell Tumor, Stage IIIB Primary Peritoneal Cancer, Stage IIIC Fallopian Tube Cancer, Stage IIIC Ovarian Cancer, Stage IIIC Ovarian Germ Cell Tumor, Stage IIIC Primary Peritoneal Cancer, Stage IV Borderline Ovarian Surface Epithelial-Stromal Tumor, Stage IV Fallopian Tube Cancer, Stage IV Ovarian Cancer, Stage IV Primary Peritoneal Cancer, Stage IV Uterine Corpus Cancer, Stage IVA Cervical Cancer, Stage IVA Vaginal Cancer, Stage IVB Cervical Cancer, Stage IVB Vaginal Cancer, Stage IVB Vulvar Cancer, Uterine Corpus Cancer, Uterine Corpus Leiomyosarcoma, Vulvar Squamous Cell Carcinoma
- Interventions
- Laboratory Biomarker Analysis
- Other
- Lead sponsor
- Gynecologic Oncology Group
- Network
- Eligibility
- Female only
- Enrollment
- 275 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- Started 1992
- U.S. locations
- 187
- States / cities
- Fayetteville, Arkansas • Little Rock, Arkansas • Burbank, California + 128 more
- Conditions
- General; Metabolic Disorder, Sexual Dysfunction, Hair Loss, Pathology
- Interventions
- Not listed
- Lead sponsor
- Roman Health Ventures Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 10,000 participants
- Timeline
- 2023 – 2033
- U.S. locations
- 1
- States / cities
- San Francisco, California
- Conditions
- PHYSIOLOGICAL PHENOMENA, Homeostasis, Physical Functional Performance, Cardiorespiratory Fitness, Cardiometabolic Risk Factors, Mobility Limitation
- Interventions
- Standardized Physiologic Resilience Challenge, Multimodal Whole-Body Physiologic Monitoring, Research-Only Whole-Body Digital Twin Analysis
- Procedure · Other
- Lead sponsor
- Truway Health, Inc.
- Industry
- Eligibility
- 18 Years to 80 Years
- Enrollment
- 450 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2026 – 2041
- U.S. locations
- 1
- States / cities
- New York, New York
- Conditions
- Healthy Volunteers
- Interventions
- Not listed
- Lead sponsor
- National Heart, Lung, and Blood Institute (NHLBI)
- NIH
- Eligibility
- 8 Years to 99 Years
- Enrollment
- 1,000 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- Started 2007
- U.S. locations
- 1
- States / cities
- Bethesda, Maryland